Author(s):
Sadia Afrin, Md. Shanzid Hasan, Md. Rezwan Ahmed Mahedi, Ovijet Chandra Kuri, Hrishik Iqbal, Mustafa Jawad Kadham, Mohammad Jamali, Patrik Viktor, Calvin R. Wei, Fredmoore Orosco, Akter Hossain Khan, Nikolaos Syrmos, Fazle Rabbi
Email(s):
rezwanmahed747@gmail.com
DOI:
10.52711/0974-360X.2024.00436 
Address:
Sadia Afrin1, Md. Shanzid Hasan2, Md. Rezwan Ahmed Mahedi3*, Ovijet Chandra Kuri4, Hrishik Iqbal5, Mustafa Jawad Kadham6, Dr. Mohammad Jamali7, Patrik Viktor8,
Calvin R. Wei9, Fredmoore Orosco10, Akter Hossain Khan11, Nikolaos Syrmos12, Fazle Rabbi13
1Department of Pharmacy, Comilla University, Bangladesh.
2Department of Pharmacy, University of Asia Pacific, Bangladesh.
1,3*Research Secretary, Bangladeshi Pharmacists’ Forum (Comilla University), Bangladesh.
4Karadeniz Teknik Universitesi.
5Department of Mathematics and Natural Sciences, Brac University, Bangladesh.
6College of Medical Techniques, Al-Farahidi University, Baghdad, Iraq.
7Faculty of Medical and Health Sciences,Liwa College, Abu Dhabi UAE.
8Óbuda University, Keleti Károly Faculty of Business and Management, Óbuda University, Tavaszmező u. 15-17, H-1084 Budapest, Hungary.
9Department of Research and Development, Shing Huei Group, Taipei, Taiwan.
10Virology and Vaccine Institute of the Philippines Progr
Published In:
Volume - 17,
Issue - 6,
Year - 2024
ABSTRACT:
Introduction. Worldwide, millions suffer from dengue fever, a mosquito-borne virus that is severe. No particular antiviral drugs exist, making dengue management difficult. New therapies like Eltrombopag Olamine, originally developed for thrombocytopenia, have shown promise. This study examines Eltrombopag Olamine's dengue fever treatment potential using literature, experimental data, and clinical implications. Methodology. This systematic review examines the available literature on the use of Eltrombopag Olamine for the treatment of dengue fever. Thorough keyword searches throughout databases like PubMed and Cochrane, as well as hand-searching of reference lists, provide a large data set for analysis. Result. The small-molecule thrombopoietin receptor agonist eltrombopag olamine showed immunomodulatory properties that are important in the treatment of dengue fever. Studies on dengue patients show that it successfully increases platelet counts, suggesting it may be useful in treating thrombocytopenia. Phase III studies are now investigating its effect on platelet counts and fluid leakage in dengue patients, which might lead to new and improved treatments in the future. Conclusion. The study highlights Eltrombopag Olamine's dengue fever management potential. Its novel approach and favorable patient results, including shortened hospital stays and improved quality of life, provide promise for dengue fever treatment. Policymakers and healthcare providers must fund more research to fully uncover its therapeutic effects. Eltrombopag Olamine might transform dengue treatment, improving efficacy and quality of life for millions.
Cite this article:
Sadia Afrin, Md. Shanzid Hasan, Md. Rezwan Ahmed Mahedi, Ovijet Chandra Kuri, Hrishik Iqbal, Mustafa Jawad Kadham, Mohammad Jamali, Patrik Viktor, Calvin R. Wei, Fredmoore Orosco, Akter Hossain Khan, Nikolaos Syrmos, Fazle Rabbi. Eltrombopag Olamine in Dengue Fever: Systematic Review of Clinical Trials and Beyond. Research Journal of Pharmacy and Technology. 2024; 17(6):2778-2. doi: 10.52711/0974-360X.2024.00436
Cite(Electronic):
Sadia Afrin, Md. Shanzid Hasan, Md. Rezwan Ahmed Mahedi, Ovijet Chandra Kuri, Hrishik Iqbal, Mustafa Jawad Kadham, Mohammad Jamali, Patrik Viktor, Calvin R. Wei, Fredmoore Orosco, Akter Hossain Khan, Nikolaos Syrmos, Fazle Rabbi. Eltrombopag Olamine in Dengue Fever: Systematic Review of Clinical Trials and Beyond. Research Journal of Pharmacy and Technology. 2024; 17(6):2778-2. doi: 10.52711/0974-360X.2024.00436 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-6-55
REFERENCE:
1. Rasana Patil, Tina Makhija, H. P. Suryawanshi, S.P. Pawar. A Review on – Dengue. Research J. Pharm. and Tech. 2013; 6(9): September 930-936.
2. Dehghani R, Kassiri H. A Review on Epidemiology of Dengue Viral Infection as an Emerging Disease. Research Journal of Pharmacy and Technology. 2021; 14(4): 2296-1. doi: 10.52711/0974-360X.2021.00406
3. Thant Z, Tengku MA, Azmi H, Norizhar K. Dengue Virus Infections: Global Scenario, Classification, and Clinical Manifestations– A Review. Research J. Pharm. and Tech. 2016; 9(1): Jan., 83-90. doi: 10.5958/0974-360X.2016.00014.7
4. Roy A, Prasad P. Dengue, hemorrhagic, serologic and virologic. Research J. Pharm. and Tech. 2013; 6(9): 937-940.
5. Bhandari R, C. S. Shastry, Chand S, R. Anusha, Arun J, Chhetri DR, H. N. Girish. Clinical and Laboratory Aspects of Dengue Fever in Tertiary Care Hospital. Research J. Pharm. and Tech. 2020; 13(12): 5783-5786. doi: 10.5958/0974-360X.2020.01008.2
6. Mahedi MRA, Rawat A, Rabbi F, Babu KS, Tasayco ES, Areche FO, Alejo OVP, Flores DDC, Aguilar SV, Orosco FL, Syrmos N, Mudhafar M, Afrin S, Rahman MM. Understanding the Global Transmission and Demographic Distribution of Nipah Virus (NiV). Research Journal of Pharmacy and Technology 2023; 16(8): 3588-4. doi: 10.52711/0974-360X.2023.00592
7. Kühne, T., Imbach, P. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Ann Hematol 2010; 89; 67–74. https://doi.org/10.1007/s00277-010-0953-x
8. Chakraborty S, Alam S, Sayem M, Sanyal M, Das T, Saha P, Sayem M, Byapari BK, Tabassum CT, Kabir A, Amin MR, Nabi AHMN. Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial. E Clinical Medicine. 2020; 29-30. doi: 10.1016/j.eclinm.2020.100624.
9. Davies, SG, Kennewell PD, Russell AJ, Silpa L, Westwood R, and Wynne GM. (2017). Regenerative Medicine. In Comprehensive Medicinal Chemistry III; 2017; 379–435. Elsevier.
10. Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016; 10:2833-2843.
11. McCrae K. Immune thrombocytopenia: no longer ‘idiopathic.’ Cleve Clin J Med. 2011;78(6):358-373.
12. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10-23.
13. Cheng G. Eltrombopag, a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol. 2012; 3(3):155-164.
14. Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol; 2005; 33: 85–93
15. GlaxoSmithKline. Promacta (eltrombopag tablets): US prescribing information; 2011.
16. Erhardt J., Erickson-Miller C.L., Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood; 2004; 104: 59b
17. Promacta. Prescribing information. Novartis Pharmaceuticals Corp; 2013.
18. Siddique N. Prevention and treatment of thrombocytopenia in dengue patients: a narrative review. Istanbul Journal of Pharmacy, 2021. https://doi.org/10.26650/istanbuljpharm.2021.854023
19. A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). Clinicaltrials.gov. 2023, from https://classic.clinicaltrials.gov/ct2/show/results/NCT01098487?view=results
20. Sri Lanka Clinical Trials Registry. Slctr.Lk. 2022, from https://slctr.lk/trials/slctr-2022-023
21. Trainee. Liver drug treatment hope for dengue fever after Dhaka research. Dhaka Tribune, 2020.
22. Arun A, Kanimozhi S, Vijayakumar M. Dietary Soups to Avert and Recuperate from Dengue Fever. Research J. Pharm. and Tech 2019; 12(9): 4142-4148. doi: 10.5958/0974-360X.2019.00715.7
23. Shahana RY, Lakshmi T. Nilavembukudineer awareness for Dengue and Chicken Gunia among Rural Community people in Tamil Nadu. Research J. Pharm. and Tech 2016; 9(12): 2135-2140. doi: 10.5958/0974-360X.2016.00433.9
24. Baheerati MM. Natural Therapy for Dengue Fever. Research J. Pharm. and Tech. 7(2): Feb. 2014; Page 269-271.
25. Shanmugapriya E, Ravichandiran V, Aanandhi MV. Molecular docking studies on naturally occurring selected flavones against protease enzyme of Dengue virus. Research J. Pharm. and Tech. 2016; 9(7):929-932. doi: 10.5958/0974-360X.2016.00178.5
26. Suganya J, Kumar GR, Radha M, Dhananya S. In silico Investigation of Natural compounds identified from Ocimum species as Dengue NS3 and NS5 Protein Inhibitors. Research Journal of Pharmacy and Technology. 2021; 14(12): 6621-6. doi: 10.52711/0974-360X.2021.01144
27. Lucy L, Prof. Terapong T, Prof. Bridget W. “Managing the Severely Ill Dengue Patients,” 2021.